nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—dilated cardiomyopathy	0.733	1	CbGaD
Pomalidomide—ABCB1—Lisinopril—dilated cardiomyopathy	0.0731	0.532	CbGbCtD
Pomalidomide—ABCB1—Spironolactone—dilated cardiomyopathy	0.0643	0.468	CbGbCtD
Pomalidomide—Thalidomide—TNF—dilated cardiomyopathy	0.00307	1	CrCbGaD
Pomalidomide—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00293	0.0344	CcSEcCtD
Pomalidomide—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.002	0.0235	CcSEcCtD
Pomalidomide—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00177	0.0208	CcSEcCtD
Pomalidomide—Renal failure—Spironolactone—dilated cardiomyopathy	0.00164	0.0193	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CSF3—dilated cardiomyopathy	0.00155	0.0371	CbGpPWpGaD
Pomalidomide—PTGS2—Synthesis of 15-eicosatetraenoic acid derivatives—GPX1—dilated cardiomyopathy	0.00132	0.0318	CbGpPWpGaD
Pomalidomide—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00125	0.0147	CcSEcCtD
Pomalidomide—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00123	0.0145	CcSEcCtD
Pomalidomide—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00122	0.0143	CcSEcCtD
Pomalidomide—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.0012	0.014	CcSEcCtD
Pomalidomide—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.00118	0.0139	CcSEcCtD
Pomalidomide—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00117	0.0137	CcSEcCtD
Pomalidomide—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00114	0.0134	CcSEcCtD
Pomalidomide—Urinary retention—Furosemide—dilated cardiomyopathy	0.00112	0.0131	CcSEcCtD
Pomalidomide—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.0011	0.013	CcSEcCtD
Pomalidomide—Dehydration—Furosemide—dilated cardiomyopathy	0.0011	0.0129	CcSEcCtD
Pomalidomide—Confusional state—Spironolactone—dilated cardiomyopathy	0.00107	0.0126	CcSEcCtD
Pomalidomide—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00107	0.0126	CcSEcCtD
Pomalidomide—TNF—Death Receptor Signalling—FASLG—dilated cardiomyopathy	0.00105	0.0253	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—NPPB—dilated cardiomyopathy	0.00105	0.0253	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00104	0.0122	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—CXCL2—dilated cardiomyopathy	0.00104	0.025	CbGpPWpGaD
Pomalidomide—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00104	0.0122	CcSEcCtD
Pomalidomide—TNF—Death Receptor Signalling—FAS—dilated cardiomyopathy	0.00102	0.0244	CbGpPWpGaD
Pomalidomide—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.000933	0.0109	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000919	0.0108	CcSEcCtD
Pomalidomide—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000919	0.0108	CcSEcCtD
Pomalidomide—Renal failure—Furosemide—dilated cardiomyopathy	0.000893	0.0105	CcSEcCtD
Pomalidomide—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.000888	0.0104	CcSEcCtD
Pomalidomide—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.000884	0.0104	CcSEcCtD
Pomalidomide—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000877	0.0103	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000859	0.0101	CcSEcCtD
Pomalidomide—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000842	0.00987	CcSEcCtD
Pomalidomide—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.000829	0.00972	CcSEcCtD
Pomalidomide—Dehydration—Lisinopril—dilated cardiomyopathy	0.000822	0.00965	CcSEcCtD
Pomalidomide—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000805	0.00945	CcSEcCtD
Pomalidomide—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000799	0.00938	CcSEcCtD
Pomalidomide—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000799	0.00937	CcSEcCtD
Pomalidomide—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000791	0.00928	CcSEcCtD
Pomalidomide—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000785	0.0092	CcSEcCtD
Pomalidomide—Pruritus—Spironolactone—dilated cardiomyopathy	0.000753	0.00884	CcSEcCtD
Pomalidomide—Angiopathy—Furosemide—dilated cardiomyopathy	0.00074	0.00868	CcSEcCtD
Pomalidomide—TNF—Apoptosis—DSG2—dilated cardiomyopathy	0.000739	0.0177	CbGpPWpGaD
Pomalidomide—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000735	0.00862	CcSEcCtD
Pomalidomide—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000729	0.00855	CcSEcCtD
Pomalidomide—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000726	0.00852	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—LMNA—dilated cardiomyopathy	0.000722	0.0174	CbGpPWpGaD
Pomalidomide—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000715	0.00838	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00071	0.00833	CcSEcCtD
Pomalidomide—Malnutrition—Furosemide—dilated cardiomyopathy	0.00071	0.00833	CcSEcCtD
Pomalidomide—Dizziness—Spironolactone—dilated cardiomyopathy	0.000704	0.00826	CcSEcCtD
Pomalidomide—Weight increased—Lisinopril—dilated cardiomyopathy	0.000696	0.00816	CcSEcCtD
Pomalidomide—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000692	0.00811	CcSEcCtD
Pomalidomide—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00069	0.00809	CcSEcCtD
Pomalidomide—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000685	0.00804	CcSEcCtD
Pomalidomide—TNF—Cardiac Hypertrophic Response—NPPA—dilated cardiomyopathy	0.000685	0.0164	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.000683	0.0164	CbGpPWpGaD
Pomalidomide—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000682	0.00801	CcSEcCtD
Pomalidomide—Vomiting—Spironolactone—dilated cardiomyopathy	0.000677	0.00794	CcSEcCtD
Pomalidomide—TNF—RXR and RAR heterodimerization with other nuclear receptor—RPS6KB1—dilated cardiomyopathy	0.000672	0.0161	CbGpPWpGaD
Pomalidomide—Rash—Spironolactone—dilated cardiomyopathy	0.000671	0.00788	CcSEcCtD
Pomalidomide—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000671	0.00787	CcSEcCtD
Pomalidomide—TNF—Cytokines and Inflammatory Response—IL10—dilated cardiomyopathy	0.00067	0.0161	CbGpPWpGaD
Pomalidomide—Renal failure—Lisinopril—dilated cardiomyopathy	0.00067	0.00786	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.000668	0.00784	CcSEcCtD
Pomalidomide—Headache—Spironolactone—dilated cardiomyopathy	0.000667	0.00782	CcSEcCtD
Pomalidomide—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000662	0.00777	CcSEcCtD
Pomalidomide—Anaemia—Furosemide—dilated cardiomyopathy	0.000656	0.0077	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—PSEN1—dilated cardiomyopathy	0.000645	0.0155	CbGpPWpGaD
Pomalidomide—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000645	0.00756	CcSEcCtD
Pomalidomide—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000643	0.00754	CcSEcCtD
Pomalidomide—Vertigo—Furosemide—dilated cardiomyopathy	0.000638	0.00748	CcSEcCtD
Pomalidomide—Leukopenia—Furosemide—dilated cardiomyopathy	0.000635	0.00745	CcSEcCtD
Pomalidomide—Nausea—Spironolactone—dilated cardiomyopathy	0.000632	0.00742	CcSEcCtD
Pomalidomide—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.000624	0.015	CbGpPWpGaD
Pomalidomide—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000604	0.00709	CcSEcCtD
Pomalidomide—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000603	0.00707	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.0006	0.00704	CcSEcCtD
Pomalidomide—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.0006	0.00704	CcSEcCtD
Pomalidomide—Confusional state—Furosemide—dilated cardiomyopathy	0.000584	0.00685	CcSEcCtD
Pomalidomide—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000568	0.00666	CcSEcCtD
Pomalidomide—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000567	0.00665	CcSEcCtD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—LMNA—dilated cardiomyopathy	0.000566	0.0136	CbGpPWpGaD
Pomalidomide—Skin disorder—Furosemide—dilated cardiomyopathy	0.000563	0.0066	CcSEcCtD
Pomalidomide—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00056	0.00657	CcSEcCtD
Pomalidomide—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000555	0.00651	CcSEcCtD
Pomalidomide—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000551	0.00647	CcSEcCtD
Pomalidomide—Chills—Lisinopril—dilated cardiomyopathy	0.000549	0.00644	CcSEcCtD
Pomalidomide—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000536	0.00629	CcSEcCtD
Pomalidomide—Malnutrition—Lisinopril—dilated cardiomyopathy	0.000533	0.00625	CcSEcCtD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FASLG—dilated cardiomyopathy	0.000531	0.0127	CbGpPWpGaD
Pomalidomide—Back pain—Lisinopril—dilated cardiomyopathy	0.000515	0.00604	CcSEcCtD
Pomalidomide—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000512	0.00601	CcSEcCtD
Pomalidomide—TNF—HIV-1 Nef: Negative effector of Fas and TNF-alpha—FAS—dilated cardiomyopathy	0.000512	0.0123	CbGpPWpGaD
Pomalidomide—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000504	0.00591	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.0005	0.00587	CcSEcCtD
Pomalidomide—Fatigue—Furosemide—dilated cardiomyopathy	0.000499	0.00586	CcSEcCtD
Pomalidomide—Tremor—Lisinopril—dilated cardiomyopathy	0.000499	0.00585	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—PSEN2—dilated cardiomyopathy	0.000496	0.0119	CbGpPWpGaD
Pomalidomide—Constipation—Furosemide—dilated cardiomyopathy	0.000495	0.00581	CcSEcCtD
Pomalidomide—Pain—Furosemide—dilated cardiomyopathy	0.000495	0.00581	CcSEcCtD
Pomalidomide—Anaemia—Lisinopril—dilated cardiomyopathy	0.000492	0.00577	CcSEcCtD
Pomalidomide—TNF—Monoamine Transport—AGT—dilated cardiomyopathy	0.000491	0.0118	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—AGTR1—dilated cardiomyopathy	0.000489	0.0117	CbGpPWpGaD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—GPX1—dilated cardiomyopathy	0.000488	0.0117	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—NPPA—dilated cardiomyopathy	0.000488	0.0117	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.000487	0.0117	CbGpPWpGaD
Pomalidomide—PTGS2—S1P1 pathway—RAC1—dilated cardiomyopathy	0.000483	0.0116	CbGpPWpGaD
Pomalidomide—Vertigo—Lisinopril—dilated cardiomyopathy	0.000479	0.00561	CcSEcCtD
Pomalidomide—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000477	0.0056	CcSEcCtD
Pomalidomide—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000477	0.00559	CcSEcCtD
Pomalidomide—Cough—Lisinopril—dilated cardiomyopathy	0.000465	0.00545	CcSEcCtD
Pomalidomide—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000458	0.00537	CcSEcCtD
Pomalidomide—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000453	0.00532	CcSEcCtD
Pomalidomide—Anxiety—Lisinopril—dilated cardiomyopathy	0.000452	0.0053	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00045	0.00528	CcSEcCtD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—RAC1—dilated cardiomyopathy	0.000448	0.0108	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—ITGB1—dilated cardiomyopathy	0.000448	0.0108	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—DSP—dilated cardiomyopathy	0.000443	0.0106	CbGpPWpGaD
Pomalidomide—Confusional state—Lisinopril—dilated cardiomyopathy	0.000438	0.00514	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—FASLG—dilated cardiomyopathy	0.000438	0.0105	CbGpPWpGaD
Pomalidomide—Infection—Lisinopril—dilated cardiomyopathy	0.000432	0.00507	CcSEcCtD
Pomalidomide—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000427	0.00501	CcSEcCtD
Pomalidomide—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000426	0.00499	CcSEcCtD
Pomalidomide—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000422	0.00495	CcSEcCtD
Pomalidomide—TNF—FAS pathway and Stress induction of HSP regulation—FAS—dilated cardiomyopathy	0.000422	0.0101	CbGpPWpGaD
Pomalidomide—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00042	0.00493	CcSEcCtD
Pomalidomide—Asthenia—Furosemide—dilated cardiomyopathy	0.000416	0.00488	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—RAC1—dilated cardiomyopathy	0.000414	0.00994	CbGpPWpGaD
Pomalidomide—Pruritus—Furosemide—dilated cardiomyopathy	0.00041	0.00481	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000408	0.00981	CbGpPWpGaD
Pomalidomide—TNF—Vitamin B12 Metabolism—SOD2—dilated cardiomyopathy	0.000405	0.00972	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000403	0.00967	CbGpPWpGaD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—RPS6KB1—dilated cardiomyopathy	0.000398	0.00957	CbGpPWpGaD
Pomalidomide—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000396	0.00465	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000396	0.00465	CcSEcCtD
Pomalidomide—Insomnia—Lisinopril—dilated cardiomyopathy	0.000393	0.00461	CcSEcCtD
Pomalidomide—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000388	0.00455	CcSEcCtD
Pomalidomide—Dizziness—Furosemide—dilated cardiomyopathy	0.000383	0.00449	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—dilated cardiomyopathy	0.000381	0.00914	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—RPS6KB1—dilated cardiomyopathy	0.00038	0.00913	CbGpPWpGaD
Pomalidomide—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000378	0.00443	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000375	0.0044	CcSEcCtD
Pomalidomide—Fatigue—Lisinopril—dilated cardiomyopathy	0.000375	0.0044	CcSEcCtD
Pomalidomide—Constipation—Lisinopril—dilated cardiomyopathy	0.000372	0.00436	CcSEcCtD
Pomalidomide—Pain—Lisinopril—dilated cardiomyopathy	0.000372	0.00436	CcSEcCtD
Pomalidomide—Vomiting—Furosemide—dilated cardiomyopathy	0.000368	0.00432	CcSEcCtD
Pomalidomide—Rash—Furosemide—dilated cardiomyopathy	0.000365	0.00428	CcSEcCtD
Pomalidomide—Dermatitis—Furosemide—dilated cardiomyopathy	0.000365	0.00428	CcSEcCtD
Pomalidomide—PTGS2—Calcium signaling in the CD4+ TCR pathway—FASLG—dilated cardiomyopathy	0.000364	0.00874	CbGpPWpGaD
Pomalidomide—Headache—Furosemide—dilated cardiomyopathy	0.000363	0.00426	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—RAC1—dilated cardiomyopathy	0.00036	0.00864	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000358	0.00861	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000358	0.0042	CcSEcCtD
Pomalidomide—Nausea—Furosemide—dilated cardiomyopathy	0.000344	0.00404	CcSEcCtD
Pomalidomide—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000344	0.00403	CcSEcCtD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—FASLG—dilated cardiomyopathy	0.000343	0.00823	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000339	0.00814	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—RAC1—dilated cardiomyopathy	0.000333	0.00801	CbGpPWpGaD
Pomalidomide—TNF—Caspase Cascade in Apoptosis—FAS—dilated cardiomyopathy	0.000331	0.00794	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—SOD2—dilated cardiomyopathy	0.000329	0.00791	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00032	0.00376	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.00032	0.00768	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—GPX1—dilated cardiomyopathy	0.000314	0.00754	CbGpPWpGaD
Pomalidomide—Asthenia—Lisinopril—dilated cardiomyopathy	0.000312	0.00366	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00031	0.00744	CbGpPWpGaD
Pomalidomide—Pruritus—Lisinopril—dilated cardiomyopathy	0.000308	0.00361	CcSEcCtD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—FASLG—dilated cardiomyopathy	0.000305	0.00732	CbGpPWpGaD
Pomalidomide—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000297	0.00349	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—LMNA—dilated cardiomyopathy	0.000293	0.00703	CbGpPWpGaD
Pomalidomide—Dizziness—Lisinopril—dilated cardiomyopathy	0.000287	0.00337	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL10—dilated cardiomyopathy	0.000284	0.00682	CbGpPWpGaD
Pomalidomide—Vomiting—Lisinopril—dilated cardiomyopathy	0.000276	0.00324	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—RAF1—dilated cardiomyopathy	0.000274	0.00659	CbGpPWpGaD
Pomalidomide—Rash—Lisinopril—dilated cardiomyopathy	0.000274	0.00321	CcSEcCtD
Pomalidomide—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000274	0.00321	CcSEcCtD
Pomalidomide—Headache—Lisinopril—dilated cardiomyopathy	0.000272	0.00319	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000272	0.00653	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—CD36—dilated cardiomyopathy	0.00027	0.00649	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000264	0.00634	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000262	0.00628	CbGpPWpGaD
Pomalidomide—Nausea—Lisinopril—dilated cardiomyopathy	0.000258	0.00303	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000255	0.00613	CbGpPWpGaD
Pomalidomide—TNF—Allograft Rejection—FAS—dilated cardiomyopathy	0.000255	0.00611	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—FAS—dilated cardiomyopathy	0.000255	0.00611	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—LMNA—dilated cardiomyopathy	0.000254	0.0061	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000252	0.00606	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FASLG—dilated cardiomyopathy	0.000251	0.00604	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000249	0.00599	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000249	0.00598	CbGpPWpGaD
Pomalidomide—TNF—Ceramide signaling pathway—RAF1—dilated cardiomyopathy	0.000247	0.00592	CbGpPWpGaD
Pomalidomide—PTGS2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000243	0.00582	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FAS—dilated cardiomyopathy	0.000242	0.00582	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—RAC1—dilated cardiomyopathy	0.000238	0.00571	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.000238	0.00571	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FASLG—dilated cardiomyopathy	0.000235	0.00565	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—AGT—dilated cardiomyopathy	0.000227	0.00545	CbGpPWpGaD
Pomalidomide—TNF—Cardiac Hypertrophic Response—RAF1—dilated cardiomyopathy	0.000221	0.00531	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—RAC1—dilated cardiomyopathy	0.000221	0.00531	CbGpPWpGaD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—dilated cardiomyopathy	0.000209	0.00502	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—RAC1—dilated cardiomyopathy	0.000203	0.00489	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CXCL2—dilated cardiomyopathy	0.000198	0.00475	CbGpPWpGaD
Pomalidomide—TNF—Downstream signaling in naïve CD8+ T cells—RAF1—dilated cardiomyopathy	0.000191	0.00459	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00019	0.00456	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.000181	0.00435	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000177	0.00424	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000175	0.0042	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000175	0.0042	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—FAS—dilated cardiomyopathy	0.000171	0.00411	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000165	0.00396	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000162	0.00388	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—AGT—dilated cardiomyopathy	0.00016	0.00385	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—RAC1—dilated cardiomyopathy	0.000159	0.00381	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000158	0.00379	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—RAF1—dilated cardiomyopathy	0.000158	0.00378	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000154	0.00371	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FASLG—dilated cardiomyopathy	0.000154	0.0037	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00015	0.0036	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000149	0.00357	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FAS—dilated cardiomyopathy	0.000148	0.00357	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—GJA1—dilated cardiomyopathy	0.000147	0.00353	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—RAF1—dilated cardiomyopathy	0.000147	0.00352	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	0.000144	0.00347	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000143	0.00343	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000141	0.00339	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	0.000139	0.00334	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000137	0.0033	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.000136	0.00328	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.00013	0.00313	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000126	0.00302	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000125	0.00299	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000123	0.00296	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000116	0.00278	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000115	0.00275	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—RAC1—dilated cardiomyopathy	0.000112	0.00269	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000112	0.00268	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000108	0.0026	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000103	0.00247	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	9.64e-05	0.00231	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	9.05e-05	0.00217	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	8.93e-05	0.00214	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	8.49e-05	0.00204	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—EGFR—dilated cardiomyopathy	8.23e-05	0.00198	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	8.17e-05	0.00196	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	8.06e-05	0.00194	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	7.98e-05	0.00192	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	7.77e-05	0.00187	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	7.62e-05	0.00183	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	7.21e-05	0.00173	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—ITGB1—dilated cardiomyopathy	7.16e-05	0.00172	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	7.01e-05	0.00168	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	7.01e-05	0.00168	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ANKRD1—dilated cardiomyopathy	6.68e-05	0.00161	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	6.52e-05	0.00157	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TAZ—dilated cardiomyopathy	6.28e-05	0.00151	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	6.21e-05	0.00149	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	6.13e-05	0.00147	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	6.12e-05	0.00147	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	6.12e-05	0.00147	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—CD36—dilated cardiomyopathy	6.11e-05	0.00147	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	5.83e-05	0.0014	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	5.83e-05	0.0014	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—RAC1—dilated cardiomyopathy	5.76e-05	0.00138	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	5.71e-05	0.00137	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—SDHA—dilated cardiomyopathy	5.68e-05	0.00136	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.6e-05	0.00135	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	5.51e-05	0.00132	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	5.4e-05	0.0013	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—EGFR—dilated cardiomyopathy	5.09e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	5.05e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—dilated cardiomyopathy	4.85e-05	0.00116	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	4.74e-05	0.00114	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	4.74e-05	0.00114	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	4.45e-05	0.00107	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	4.03e-05	0.000967	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—RAF1—dilated cardiomyopathy	3.82e-05	0.000917	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	3.78e-05	0.000908	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	3.58e-05	0.00086	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	3.56e-05	0.000854	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NPPA—dilated cardiomyopathy	3.47e-05	0.000834	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.47e-05	0.000832	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	3.46e-05	0.000832	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.38e-05	0.000811	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PSEN2—dilated cardiomyopathy	3.36e-05	0.000808	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	3.3e-05	0.000792	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	3.22e-05	0.000772	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.04e-05	0.00073	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.92e-05	0.000701	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.74e-05	0.000659	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—EGFR—dilated cardiomyopathy	2.62e-05	0.000629	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	2.48e-05	0.000596	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	2.46e-05	0.00059	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	2.34e-05	0.000562	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.96e-05	0.000471	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.91e-05	0.000459	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.72e-05	0.000413	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RAC1—dilated cardiomyopathy	1.69e-05	0.000406	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPX1—dilated cardiomyopathy	1.54e-05	0.000371	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CD36—dilated cardiomyopathy	1.5e-05	0.000361	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	1.42e-05	0.000341	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—AGT—dilated cardiomyopathy	1.35e-05	0.000325	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RAF1—dilated cardiomyopathy	1.12e-05	0.000269	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	1.09e-05	0.000263	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CD36—dilated cardiomyopathy	1.07e-05	0.000256	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—AGT—dilated cardiomyopathy	9.59e-06	0.00023	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	8.74e-06	0.00021	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	8.51e-06	0.000204	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—EGFR—dilated cardiomyopathy	7.69e-06	0.000185	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	7.66e-06	0.000184	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	6.74e-06	0.000162	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	6.57e-06	0.000158	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	5.91e-06	0.000142	CbGpPWpGaD
